Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy.
about
Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study.Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.Prevention of chemotherapy-induced peripheral neuropathy by the small-molecule inhibitor pifithrin-μ.Distal retinal ganglion cell axon transport loss and activation of p38 MAPK stress pathway following VEGF-A antagonism.VEGF-VEGFR Signals in Health and Disease.VEGF ligands and receptors: implications in neurodevelopment and neurodegeneration.Endogenous recovery after brain damage: molecular mechanisms that balance neuronal life/death fate.Pharmacology of Modulators of Alternative Splicing.Recent drug therapies for corneal neovascularization.Neuropathic Pain Components in Patients with Cancer: Prevalence, Treatment, and Interference with Daily Activities.The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain.Cisplatin induced sensory neuropathy is prevented by vascular endothelial growth factor-A.Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia.Taxane-Induced Peripheral Neurotoxicity.Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy.Quantification of edematous changes by diffusion magnetic resonance imaging in gastrocnemius muscles after spinal nerve ligation.Conditioned Medium of Bone Marrow-Derived Mesenchymal Stromal Cells as a Therapeutic Approach to Neuropathic Pain: A Preclinical Evaluation.
P2860
Q36228462-E0B3AFF4-1D1D-40CB-A74C-F71BD245A89BQ36428702-8021D1E4-2696-496A-ACE2-E753BE636B49Q36988206-897E53DC-7892-42CE-983F-2E16F4C82693Q37030276-C42438FC-1A9E-42F4-B266-7189D4E19AD9Q37606226-C1321B1A-D423-46A4-95C7-EF94F4C15A18Q38087877-BDB60DCF-377C-4E9F-A221-8942D40E7B3CQ38587925-31B0C0B0-034A-4887-AEA3-E453319C4A6FQ38776406-4805D6BF-03AC-4B6C-8766-8FED09C4AD2EQ39295602-44E31A14-E82B-446F-8E39-4EDC541BD3D0Q41096755-E5419C98-F57E-4954-868B-E88D5CF7ACFFQ41853439-166BD107-0A9F-4C9A-A460-59FB93E45C69Q41949087-3A5C603B-48F4-443A-A31A-55A91739FE74Q41953953-BF6FA1B2-4A77-42E3-9964-7EFE2FFE45ADQ45759415-B22724A5-E083-406D-87A1-4EABF961A398Q47151258-6F1F3D30-450B-4856-9ADF-75CD625364A2Q52374791-696D7963-C97D-4FE6-AC5A-E7F318A21A30Q55278639-3DF7131B-3803-4667-A81A-139BDFDA5028
P2860
Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Systemic anti-vascular endothe ...... a painful sensory neuropathy.
@en
Systemic anti-vascular endothe ...... a painful sensory neuropathy.
@nl
type
label
Systemic anti-vascular endothe ...... a painful sensory neuropathy.
@en
Systemic anti-vascular endothe ...... a painful sensory neuropathy.
@nl
prefLabel
Systemic anti-vascular endothe ...... a painful sensory neuropathy.
@en
Systemic anti-vascular endothe ...... a painful sensory neuropathy.
@nl
P2093
P2860
P50
P356
P1433
P1476
Systemic anti-vascular endothe ...... a painful sensory neuropathy.
@en
P2093
An Verheyen
Anneleen Daniels
Eve Peeraer
Isabel Pintelon
Joke Dhondt
Koen Poesen
Rony Nuydens
Theo Meert
P2860
P304
P356
10.1093/BRAIN/AWS145
P407
P577
2012-06-25T00:00:00Z